Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

ion, the reductions in A1C and FPG with JANUVIA compared to placebo were generally similar to those observed in other monotherapy studies. (See Clinical Pharmacology (12.3).) 14.2 Combination Therapy Combination Therapy with Metformin A total of 701 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of JANUVIA in combination with metformin. Patients already on metformin (N=431) at a dose of at least 1500 mg per day were randomized after completing a 2-week single-blind placebo run-in period. Patients on metformin and another antihyperglycemic agent (N = 229) and patients not on any antihyperglycemic agents (off therapy for at least 8 weeks, N = 41) were randomized after a run-in period of approximately 10 weeks on metformin (at a dose of at least 1500 mg per day) in monotherapy. Patients were randomized to the addition of either 100 mg of JANUVIA or placebo, administered once daily. Patients who failed to meet specific glycemic goals during the studies were treated with pioglitazone rescue. In combination with metformin, JANUVIA provided significant improvements in A1C, FPG, and 2-hour PPG compared to placebo with metformin (Table 3). Rescue glycemic therapy was used in 5% of patients treated with JANUVIA 100 mg and 14% of patients treated with placebo. A similar decrease in body weight was observed for both treatment groups. Table 3 Glycemic Parameters at Final Visit (24-Week Study) for JANUVIA in Combination with Metformin+ ---------------------------------------------------------------------- JANUVIA Placebo + 100 mg + Metformin Metformin ----------------------------------------------------------- --------- A1C (%)
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... products from Teva Pharmaceuticals in connection with Teva,s acquisition ... own the ANDAs of fentanyl citrate lozenges, a generic ... version of Amrix®, as well as the U.S. rights ...
... 18, 2011 Tourists visiting the "Happiest Place on ... not able to experience it. Not all guests visiting ... walk the theme parks. Some people may appear healthy ... walking for long periods of time. Conditions stemming from ...
Cached Medicine Technology:Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 2
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... December 25, 2014 Over 700 toys, ... their local communities. That is 700 smiling little faces ... gift. Additionally over $6000 in monetary donations was given ... some of the expenses they incur through the year. ... were A Child's Haven , Shrine's Children's Hospitals, ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... , PROVO, Utah , Jan. 19 ... announced that it will release fourth quarter financial results prior to the ... Hunt , president and chief executive officer, will host a conference call ... a.m. (EDT) . During the call, participants can expect to hear management ...
... , ANN ARBOR, Mich. , ... and MEDITECH have collaborated to offer content from the Micromedex ... Care Information System (HCIS) — Emergency Department Management, Physician Care ... one of the Micromedex clinical evidence solutions from Thomson Reuters, ...
... , ATLANTA , Jan. 19 ... of the Unit of Interventional Radiology at the European Institute ... 2010 Best Poster Award by Dr. Shaun Samuels , ... Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors. ...
... health care, particularly at the end of life, may incite ... Hopkins emeritus professor of neurology called for the start of ... month,s issue of the Journal of Medical Ethics . ... Emeritus of Pediatric Neurology and a faculty member of the ...
... infection, researchers find , TUESDAY, Jan. 19 (HealthDay News) -- ... treatment for sickle cell disease, a common genetic disorder, new ... in the Journal of Clinical Investigation , are based ... with the disease will benefit from treatment with statins. ...
... chromosome component, research shows , TUESDAY, Jan. 19 (HealthDay ... of the reasons why omega-3 fatty acids are good for ... heart disease consumed, the slower their telomeres shrank. Telomeres are ... the more times a cell divides, making them a marker ...
Cached Medicine News:Health News:Nu Skin Enterprises to Announce Fourth Quarter and Annual 2009 Results 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Reasoning through the rationing of end-of-life care 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 3
0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
Medicine Products: